◼ Archived
Business
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
1 trends tracked about this subject — the full history, oldest to newest below.
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.